Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis
Context Chinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.Objective To assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Pharmaceutical Biology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13880209.2024.2312217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136248611110912 |
|---|---|
| author | Fei Ma Qun Wang Di Zhang Zihong Wang Hui Xie Xianghong Liu Hongxing Zhang Haiyan Song Shiguang Sun |
| author_facet | Fei Ma Qun Wang Di Zhang Zihong Wang Hui Xie Xianghong Liu Hongxing Zhang Haiyan Song Shiguang Sun |
| author_sort | Fei Ma |
| collection | DOAJ |
| description | Context Chinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.Objective To assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP).Materials and methods Randomized controlled trials (RCTs) were searched in databases including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science from inception to September 2023. We calculated the risk ratio with a 95% confidence interval and the surface under the cumulative ranking area curve (SUCRA) for the clinical efficacy rate (CER), the efficacy rate by Karnofsky Performance Status (KPS), and the rates of leukopenia reduction (LRR) and gastrointestinal reactions (GRR).Results Forty-seven RCTs were included, including nine CMI types: Aidi, Fufangkushen, Huangqi, Kangai (KA), Kanglaite (KLT), Renshenduotang, Shenqifuzheng (SQFZ), Shenmai (SM), and Yadanzi. KLT and KA were likely optimal choices with radiotherapy for CER and KPS, respectively. KA and KLT were optimal choices with RT + DDP for CER and GRR, respectively. KLT was the likely optimal choice with RT + DP for CER and KA for both KPS and GRR. SM and SQFZ were the likely optimal choices with RT + TP for CER and LRR, respectively.Conclusions The optimal recommendation depends on whether CMIs are used with radiotherapy or concurrent chemoradiotherapy. More high-quality RCTs are needed to confirm further and update the existing evidence. |
| format | Article |
| id | doaj-art-6602e966b06b4f5f839c9fc63c1aed4d |
| institution | Kabale University |
| issn | 1388-0209 1744-5116 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Pharmaceutical Biology |
| spelling | doaj-art-6602e966b06b4f5f839c9fc63c1aed4d2024-12-09T07:41:45ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162024-12-0162117018210.1080/13880209.2024.2312217Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysisFei Ma0Qun Wang1Di Zhang2Zihong Wang3Hui Xie4Xianghong Liu5Hongxing Zhang6Haiyan Song7Shiguang Sun8Office of Party Committee (Director), Affiliated Hospital, Shandong Provincial Hospital of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, ChinaDepartment of Pharmacy, Qilu Hospital, Shandong University, Jinan, ChinaDepartment of Pharmacy, Jinan Hospital of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaDepartment of Pharmacy, Second Affiliated Hospital, Shandong Provincial Hospital of Integrated Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, ChinaContext Chinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.Objective To assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP).Materials and methods Randomized controlled trials (RCTs) were searched in databases including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science from inception to September 2023. We calculated the risk ratio with a 95% confidence interval and the surface under the cumulative ranking area curve (SUCRA) for the clinical efficacy rate (CER), the efficacy rate by Karnofsky Performance Status (KPS), and the rates of leukopenia reduction (LRR) and gastrointestinal reactions (GRR).Results Forty-seven RCTs were included, including nine CMI types: Aidi, Fufangkushen, Huangqi, Kangai (KA), Kanglaite (KLT), Renshenduotang, Shenqifuzheng (SQFZ), Shenmai (SM), and Yadanzi. KLT and KA were likely optimal choices with radiotherapy for CER and KPS, respectively. KA and KLT were optimal choices with RT + DDP for CER and GRR, respectively. KLT was the likely optimal choice with RT + DP for CER and KA for both KPS and GRR. SM and SQFZ were the likely optimal choices with RT + TP for CER and LRR, respectively.Conclusions The optimal recommendation depends on whether CMIs are used with radiotherapy or concurrent chemoradiotherapy. More high-quality RCTs are needed to confirm further and update the existing evidence.https://www.tandfonline.com/doi/10.1080/13880209.2024.2312217Chinese medicine injections (CMIs)Radiotherapy (RT)concurrent chemoradiotherapy (CCRT)efficacysafetynetwork meta-analysis |
| spellingShingle | Fei Ma Qun Wang Di Zhang Zihong Wang Hui Xie Xianghong Liu Hongxing Zhang Haiyan Song Shiguang Sun Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis Pharmaceutical Biology Chinese medicine injections (CMIs) Radiotherapy (RT) concurrent chemoradiotherapy (CCRT) efficacy safety network meta-analysis |
| title | Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis |
| title_full | Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis |
| title_fullStr | Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis |
| title_full_unstemmed | Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis |
| title_short | Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis |
| title_sort | comparative efficacy and safety of chinese medicine injections as an adjunctive therapy for cervical cancer in chinese patients a network meta analysis |
| topic | Chinese medicine injections (CMIs) Radiotherapy (RT) concurrent chemoradiotherapy (CCRT) efficacy safety network meta-analysis |
| url | https://www.tandfonline.com/doi/10.1080/13880209.2024.2312217 |
| work_keys_str_mv | AT feima comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis AT qunwang comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis AT dizhang comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis AT zihongwang comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis AT huixie comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis AT xianghongliu comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis AT hongxingzhang comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis AT haiyansong comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis AT shiguangsun comparativeefficacyandsafetyofchinesemedicineinjectionsasanadjunctivetherapyforcervicalcancerinchinesepatientsanetworkmetaanalysis |